Skip to main content

Advertisement

SpringerLink
Log in

Biomarkers for prostate cancer

  • Topic Paper
  • Published:
World Journal of Urology Aims and scope Submit manuscript

Abstract

Novel biomarkers for prostate cancer (PCa) are currently being assessed for utility in PCa diagnosis. This article aims to provide concise information on the current findings that impact prostate cancer research. Results of enzyme-linked immunosorbent assays (ELISA) for single biomarkers, quantitative polymerase chain reaction (PCR)-based assays for DNA/RNA markers will be reviewed in addition to high-throughput proteomic profiling of PCa specimens. The advantages/disadvantages of tissue, blood, urine or seminal plasma as sources for potential biomarkers are discussed emphasizing the consequences for PCa diagnosis. In summary, the majority of promising marker candidates available today needs further validation. Some of the identified markers have the potential to yield novel prognostic tools for PCa, provide novel insights into its pathophysiology, and contribute to the establishment of novel treatment strategies.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Gronberg H (2003) Prostate cancer epidemiology. Lancet 361:859–864

    Article  PubMed  Google Scholar 

  2. Stamey TA, Yang N, Hay AR, McNeal JE, Freiha FS, Redwine E (1987) Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. N Engl J Med 317:909–916

    Article  PubMed  CAS  Google Scholar 

  3. Jemal A, Siegel R, Ward E, Murray T, Xu J, Smigal C, Thun MJ (2006) Cancer statistics, 2006. CA Cancer J Clin 56:106–130

    Article  PubMed  Google Scholar 

  4. Presti JC Jr (2000) Prostate cancer: assessment of risk using digital rectal examination, tumor grade, prostate-specific antigen, and systematic biopsy. Radiol Clin North Am 38:49–58

    Article  PubMed  Google Scholar 

  5. Thompson IM, Goodman PJ, Tangen CM, Lucia MS, Miller GJ, Ford LG, Lieber MM, Cespedes RD, Atkins JN, Lippman SM, Carlin SM, Ryan A, Szczepanek CM, Crowley JJ, Coltman CA Jr (2003) The influence of finasteride on the development of prostate cancer. N Engl J Med 349:215–224

    Article  PubMed  CAS  Google Scholar 

  6. Thompson IM, Pauler DK, Goodman PJ, Tangen CM, Lucia MS, Parnes HL, Minasian LM, Ford LG, Lippman SM, Crawford ED, Crowley JJ, Coltman CA Jr (2004) Prevalence of prostate cancer among men with a prostate-specific antigen level < or = 4.0 ng per milliliter. N Engl J Med 350:2239–2246

    Article  PubMed  CAS  Google Scholar 

  7. Emmert-Buck MR, Bonner RF, Smith PD, Chuaqui RF, Zhuang Z, Goldstein SR, Weiss RA, Liotta LA (1996) Laser capture microdissection. Science 274:998–1001

    Article  PubMed  CAS  Google Scholar 

  8. Fend F, Kremer M, Quintanilla-Martinez L (2000) Laser capture microdissection: methodical aspects and applications with emphasis on immuno-laser capture microdissection. Pathobiology 68:209–214

    Article  PubMed  CAS  Google Scholar 

  9. Diaz JI, Cazares LH, Corica A, John SO (2004) Selective capture of prostatic basal cells and secretory epithelial cells for proteomic and genomic analysis. Urol Oncol 22:329–336

    PubMed  CAS  Google Scholar 

  10. Cheung PK, Woolcock B, Adomat H, Sutcliffe M, Bainbridge TC, Jones EC, Webber D, Kinahan T, Sadar M, Gleave ME, Vielkind J (2004) Protein profiling of microdissected prostate tissue links growth differentiation factor 15 to prostate carcinogenesis. Cancer Res 64:5929–5933

    Article  PubMed  CAS  Google Scholar 

  11. Varambally S, Yu J, Laxman B, Rhodes DR, Mehra R, Tomlins SA, Shah RB, Chandran U, Monzon FA, Becich MJ, Wei JT, Pienta KJ, Ghosh D, Rubin MA, Chinnaiyan AM (2005) Integrative genomic and proteomic analysis of prostate cancer reveals signatures of metastatic progression. Cancer Cell 8:393–406

    Article  PubMed  CAS  Google Scholar 

  12. Bismar TA, Demichelis F, Riva A, Kim R, Varambally S, He L, Kutok J, Aster JC, Tang J, Kuefer R, Hofer MD, Febbo PG, Chinnaiyan AM, Rubin MA (2006) Defining aggressive prostate cancer using a 12-gene model. Neoplasia 8:59–68

    Article  PubMed  CAS  Google Scholar 

  13. Liu AY, Zhang H, Sorensen CM, Diamond DL (2005) Analysis of prostate cancer by proteomics using tissue specimens. J Urol 173:73–78

    Article  PubMed  CAS  Google Scholar 

  14. Johansson B, Pourian MR, Chuan YC, Byman I, Bergh A, Pang ST, Norstedt G, Bergman T, Pousette A (2006) Proteomic comparison of prostate cancer cell lines LNCaP-FGC and LNCaP-r reveals heatshock protein 60 as a marker for prostate malignancy. Prostate 66:1235–1244

    Article  PubMed  CAS  Google Scholar 

  15. Uetsuki H, Tsunemori H, Taoka R, Haba R, Ishikawa M, Kakehi Y (2005) Expression of a novel biomarker, EPCA, in adenocarcinomas and precancerous lesions in the prostate. J Urol 174:514–518

    Article  PubMed  Google Scholar 

  16. Paul B, Dhir R, Landsittel D, Hitchens MR, Getzenberg RH (2005) Detection of prostate cancer with a blood-based assay for early prostate cancer antigen. Cancer Res 65:4097–4100

    Article  PubMed  CAS  Google Scholar 

  17. Adam BL, Qu Y, Davis JW, Ward MD, Clements MA, Cazares LH, Semmes OJ, Schellhammer PF, Yasui Y, Feng Z, Wright GL Jr (2002) Serum protein fingerprinting coupled with a pattern-matching algorithm distinguishes prostate cancer from benign prostate hyperplasia and healthy men. Cancer Res 62:3609–3614

    PubMed  CAS  Google Scholar 

  18. Kolch W, Mischak H, Chalmers MJ, Pitt A, Marshall AG (2004) Clinical proteomics: a question of technology. Rapid Commun. Mass Spectrom 18:2365

    CAS  Google Scholar 

  19. Check E (2004) Running before we can walk, 429 edn. pp 496–497

  20. Baggerly KA, Morris JS, Edmonson SR, Coombes KR (2005) Signal in noise: evaluating reported reproducibility of serum proteomic tests for ovarian cancer. J Natl Cancer Inst 97:307–309

    Article  PubMed  CAS  Google Scholar 

  21. Baggerly KA, Morris JS, Coombes KR (2002) Reproducibility of SELDI-TOF protein patterns in serum: comparing datasets from different experiments. Bioinformatics 20:777–785

    Article  CAS  Google Scholar 

  22. Cheng AJ, Chen LC, Chien KY, Chen YJ, Chang JT, Wang HM, Liao CT, Chen IH (2005) Oral cancer plasma tumor marker identified with bead-based affinity-fractionated proteomic technology. Clin Chem 51:2236–2244

    Article  PubMed  CAS  Google Scholar 

  23. Tolson JP, Flad T, Gnau V, Dihazi H, Hennenlotter J, Beck A, Mueller GA, Kuczyk M, Mueller CA (2006) Differential detection of S100A8 in transitional cell carcinoma of the bladder by pair wise tissue proteomic and immunohistochemical analysis. Proteomics 6:697–708

    Article  PubMed  CAS  Google Scholar 

  24. Kolch W, Neususs C, Pelzing M, Mischak H (2005) Capillary electrophoresis–mass spectrometry as a powerful tool in clinical diagnosis and biomarker discovery. Mass Spectrom Rev 24:959–977

    Article  PubMed  CAS  Google Scholar 

  25. Schaub S, Wilkins J, Weiler T, Sangster K, Rush D, Nickerson P (2004) Urine protein profiling with surface-enhanced laser-desorption/ionization time-of-flight mass spectrometry. Kidney Int 65:323–332

    Article  PubMed  CAS  Google Scholar 

  26. Theodorescu D, Wittke S, Ross MM, Walden M, Conaway M, Just I, Mischak H, Frierson HF (2006) Discovery and validation of new protein biomarkers for urothelial cancer: a prospective analysis. Lancet Oncol 7:230–240

    Article  PubMed  CAS  Google Scholar 

  27. Harden SV, Guo Z, Epstein JI, Sidransky D (2003) Quantitative GSTP1 methylation clearly distinguishes benign prostatic tissue and limited prostate adenocarcinoma. J Urol 169:1138–1142

    Article  PubMed  CAS  Google Scholar 

  28. Goessl C, Krause H, Muller M, Heicappell R, Schrader M, Sachsinger J, Miller K (2000) Fluorescent methylation-specific polymerase chain reaction for DNA-based detection of prostate cancer in bodily fluids. Cancer Res 60:5941–5945

    PubMed  CAS  Google Scholar 

  29. Jeronimo C, Usadel H, Henrique R, Silva C, Oliveira J, Lopes C, Sidransky D (2002) Quantitative GSTP1 hypermethylation in bodily fluids of patients with prostate cancer. Urology 60:1131–1135

    Article  PubMed  Google Scholar 

  30. Gonzalgo ML, Pavlovich CP, Lee SM, Nelson WG (2003) Prostate cancer detection by GSTP1 methylation analysis of postbiopsy urine specimens. Clin Cancer Res 9:2673–2677

    PubMed  CAS  Google Scholar 

  31. Goessl C, Muller M, Heicappell R, Krause H, Straub B, Schrader M, Miller K (2001) DNA-based detection of prostate cancer in urine after prostatic massage. Urology 58:335–338

    Article  PubMed  CAS  Google Scholar 

  32. Crocitto LE, Korns D, Kretzner L, Shevchuk T, Blair SL, Wilson TG, Ramin SA, Kawachi MH, Smith SS (2004) Prostate cancer molecular markers GSTP1 and hTERT in expressed prostatic secretions as predictors of biopsy results. Urology 64:821–825

    Article  PubMed  Google Scholar 

  33. Hoque MO, Topaloglu O, Begum S, Henrique R, Rosenbaum E, Van Criekinge W, Westra WH, Sidransky D (2005) Quantitative methylation-specific polymerase chain reaction gene patterns in urine sediment distinguish prostate cancer patients from control subjects. J Clin Oncol 23:6569–6575

    Article  PubMed  CAS  Google Scholar 

  34. Bussemakers MJ, van BA, Verhaegh GW, Smit FP, Karthaus HF, Schalken JA, Debruyne FM, Ru N, Isaacs WB (1999) DD3: a new prostate-specific gene, highly overexpressed in prostate cancer. Cancer Res 59:5975–5979

  35. de Kok JB, Verhaegh GW, Roelofs RW, Hessels D, Kiemeney LA, Aalders TW, Swinkels DW, Schalken JA (2002) DD3(PCA3), a very sensitive and specific marker to detect prostate tumors. Cancer Res 62:2695–2698

    PubMed  Google Scholar 

  36. Hessels D, Klein Gunnewiek JM, van OI, Karthaus HF, van Leenders GJ, van Balken B, Kiemeney LA, Witjes JA, Schalken JA (2003) DD3(PCA3)-based molecular urine analysis for the diagnosis of prostate cancer. Eur Urol 44:8–15

  37. Sommerfeld HJ, Meeker AK, Piatyszek MA, Bova GS, Shay JW, Coffey DS (1996) Telomerase activity: a prevalent marker of malignant human prostate tissue. Cancer Res 56:218–222

    PubMed  CAS  Google Scholar 

  38. Kallakury BV, Brien TP, Lowry CV, Muraca PJ, Fisher HA, Kaufman RP Jr, Ross JS (1997) Telomerase activity in human benign prostate tissue and prostatic adenocarcinomas. Diagn Mol Pathol 6:192–198

    Article  PubMed  CAS  Google Scholar 

  39. Fernandez C, Rifai N, Wenger AS, Mickey DD, Silverman LM (1986) A preliminary study of urinary transferrin as a marker for prostatic cancer. Clin Chim Acta 161:335–339

    Article  PubMed  CAS  Google Scholar 

  40. Teni TR, Sheth AR, Kamath MR, Sheth NA (1988) Serum and urinary prostatic inhibin-like peptide in benign prostatic hyperplasia and carcinoma of prostate. Cancer Lett 43:9–14

    Article  PubMed  CAS  Google Scholar 

  41. Hutchinson LM, Chang EL, Becker CM, Ushiyama N, Behonick D, Shih MC, DeWolf WC, Gaston SM, Zetter BR (2005) Development of a sensitive and specific enzyme-linked immunosorbent assay for thymosin beta15, a urinary biomarker of human prostate cancer. Clin Biochem 38:558–571

    Article  PubMed  CAS  Google Scholar 

  42. Rogers CG, Yan G, Zha S, Gonzalgo ML, Isaacs WB, Luo J, De Marzo AM, Nelson WG, Pavlovich CP (2004) Prostate cancer detection on urinalysis for alpha methylacyl coenzyme a racemase protein. J Urol 172:1501–1503

    Article  PubMed  CAS  Google Scholar 

  43. Lwaleed BA, Francis JL, Chisholm M (2000) Urinary tissue factor levels in patients with bladder and prostate cancer. Eur J Surg Oncol 26:44–49

    Article  PubMed  CAS  Google Scholar 

  44. Stoeber K, Swinn R, Prevost AT, Clive-Lowe P, Halsall I, Dilworth SM, Marr J, Turner WH, Bullock N, Doble A, Hales CN, Williams GH (2002) Diagnosis of genito-urinary tract cancer by detection of minichromosome maintenance 5 protein in urine sediments. J Natl Cancer Inst 94:1071–1079

    PubMed  CAS  Google Scholar 

  45. Rehman I, Azzouzi AR, Catto JW, Allen S, Cross SS, Feeley K, Meuth M, Hamdy FC (2004) Proteomic analysis of voided urine after prostatic massage from patients with prostate cancer: a pilot study. Urology 64:1238–1243

    Article  PubMed  CAS  Google Scholar 

  46. M’koma AE, Blum DL, Norris JL, Koyama T, Billheimer D, Motley S, Ghiassi M, Ferdowsi N, Bhowmick I, Chang SS, Fowke JH, Caprioli RM, Bhowmick NA (2006) Detection of pre-neoplastic and neoplastic prostate disease by MADI profiling of urine. Biochem Biophys Res Commun

  47. Theodorescu D, Fliser D, Wittke S, Mischak H, Krebs R, Walden M, Ross M, Eltze E, Bettendorf O, Wulfing C, Semjonow A (2005) Pilot study of capillary electrophoresis coupled to mass spectrometry as a tool to define potential prostate cancer biomarkers in urine. Electrophoresis 26:2797–2808

    Article  PubMed  CAS  Google Scholar 

  48. Wittke S, Schiffer E, Bauer HW (2007) Kapillarelektrophorese gekoppelte Massenspektrometrie zur Proteomanalyse als innovative diagnostische Methode bei Prostata- und Blasenkrebs. Der Urologe (in press)

  49. Obiezu CV, Shan SJ, Soosaipillai A, Luo LY, Grass L, Sotiropoulou G, Petraki CD, Papanastasiou PA, Levesque MA, Diamandis EP (2005) Human kallikrein 4: quantitative study in tissues and evidence for its secretion into biological fluids. Clin Chem 51:1432–1442

    Article  PubMed  CAS  Google Scholar 

  50. Acevedo B, Perera Y, Torres E, Penton D, Ayala M, Gavilondo J (2006) Fast and novel purification method to obtain the prostate specific antigen (PSA) from human seminal plasma. Prostate 66:1029–1036

    Article  PubMed  CAS  Google Scholar 

  51. Pilch B, Mann M (2006) Large-scale and high-confidence proteomic analysis of human seminal plasma. Genome Biol 7:R40

    Article  PubMed  CAS  Google Scholar 

  52. Mischak H, Apweiler R, Banks RE, Conaway M, Coon JJ, Dominizak A, Ehrich JH, Fliser D, Girolami M, Hermjakob H, Hochstrasser DF, Jankowski V, Julian BA, Kolch W, Massy Z, Neususs C, Novak J, Peter K, Rossing K, Schanstra JP, Semmes OJ, Theodorescu D, Thongboonkerd V, Weissinger EM, Van Eyk JE, Yamamoto T (2007) Clinical proteomics: a need to define the field and to begin to set adequate standards. PROTEOMICS—Clin Appl 1:148–156

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Mosaiques Diagnostics and Therapeutics AG, Mellendorfer Str. 7-9, 30625, Hannover, Germany

    Eric Schiffer

Authors
  1. Eric Schiffer
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Eric Schiffer.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Schiffer, E. Biomarkers for prostate cancer. World J Urol 25, 557–562 (2007). https://doi.org/10.1007/s00345-007-0203-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00345-007-0203-6

Keywords

Search

Navigation